keyword
MENU ▼
Read by QxMD icon Read
search

cik cytokine induced killer

keyword
https://www.readbyqxmd.com/read/29400599/a-prognosis-and-impact-factor-analysis-of-dc-cik-cell-therapy-for-patients-with-hepatocellular-carcinoma-undergoing-postoperative-tace
#1
Jian Zhang, Huizhong Li, Dazhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Mengxue Wei, Rui Duan, Maomao Guo, Jiajun Hua, Qian Liu, Jin Bai, Hui Liu, Junnian Zheng, Hong Yao
Dendritic cell-cytokine-induced killer (DC-CIK) cell therapy has been experimentally implemented for enhancing anti-tumoral immunity in patients with hepatocellular carcinoma (HCC) undergoing postoperative transcatheter arterial chemoembolization (POTACE). We performed a retrospective study to evaluate the clinical efficacies of DC-CIK cell therapy and its correlations with several immune factors of the primary tumors. The overall survival time of HCC patients with HBV infection in the study group (POTACE plus DC-CIK cell therapy) was significantly longer than that of the control group (POTACE alone)...
February 5, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29399145/lentiviral-delivery-of-ctla-4-shrna-improves-the-expansion-of-cytokine-induced-killer-cells-and-enhances-cytotoxic-activity-in-vitro
#2
Tao Rui, Xiangdong Cheng, Hao Wu, Fuwei Wang, Zaiyuan Ye, Guoqing Wu
Cytokine-induced killer (CIK) cells are in vitro-expanded cells harboring potent toxicity against tumor cells. Recently, it was identified that the cytotoxicity and proliferation of CIK cells are restricted by a prolonged CIK cell culture period. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) serves a negative role in T cell activation and proliferation. This study aims to determine whether CTLA-4 expression is associated with the inhibition of CIK cells. CIK cells were generated from peripheral blood mononuclear cells (PBMCs), and CTLA-4 shRNA (shCTLA-4) lentivirus was applied to knockdown CTLA-4 expression in CIK cells...
January 2018: Oncology Letters
https://www.readbyqxmd.com/read/29399130/clinical-value-of-pro-grp-and-t-lymphocyte-subpopulation-for-the-assessment-of-immune-functions-of-lung-cancer-patients-after-dc-cik-biological-therapy
#3
Lijie He, Jing Wang, Dandan Chang, Dandan Lv, Haina Li, Heping Zhang
The present study investigated the aptness of assessing the levels of progastrin-releasing peptide (Pro-GRP) in addition to the T lymphocyte subpopulation in lung cancer patients prior to and after therapy for determining immune function. A total of 45 patients with lung cancer were recruited and stratified in to a non-small cell lung cancer (NSCLC) and an SCLC group. Prior to and after treatment by combined biological therapy comprising chemotherapy or chemoradiotherapy followed by three cycles of retransformation of autologous dendritic cells-cytokine-induced killer cells (DC-CIK), the peripheral blood was assessed for populations of CD3+, CD4+, CD8+ and regulatory T cells (Treg) by flow cytometry, and for the levels of pro-GRP, carcinoembryonic antigen, neuron-specific enolase and Cyfra 21-1...
February 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29370095/innovative-clinical-perspectives-for-cik-cells-in-cancer-patients
#4
REVIEW
Martino Introna, Fabio Correnti
Cytokine-induced killer (CIK) cells are T lymphocytes that have acquired, in vitro, following extensive manipulation by Interferon gamma (IFN-γ), OKT3 and Interleukin 2 (IL-2) addition, the expression of several Natural Killer (NK) cell-surface markers. CIK cells have a dual "nature", due to the presence of functional TCR as well as NK molecules, even if the antitumoral activity can be traced back only to the NK-like structures (DNAM-1, NKG2D, NKp30 and CD56). In addition to antineoplastic activity in vitro and in several in-vivo models, CIK cells show very limited, if any, GvHD toxicity as well as a strong intratumoral homing...
January 25, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29356308/high-number-of-pd-1-positive-intratumoral-lymphocytes-predict-survival-benefit-of-cik-cells-for-hepatocellular-carcinoma-patients
#5
Boyang Chang, Lujun Shen, Kefeng Wang, Jietian Jin, Tao Huang, Qifeng Chen, Wang Li, Peihong Wu
BACKGROUND & AIMS: Adjuvant cytokine-induced killer (CIK) cells treatment has shown potential in reducing the recurrence rate and prolonging the survival of patients with hepatocellular carcinoma (HCC). We aimed to identify the best predictive biomarker for adjuvant CIK cells treatment in patients with HCC after curative resection. METHODS: This study retrospectively included 145 pairs of HCC patients by one-to-one propensity score matching. One group received CIK cells transfusion after surgery (Surgery-CIK group); the other one group underwent surgery only (Surgery-only group)...
January 22, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29344236/alterations-in-expression-levels-of-genes-in-p53-related-pathways-determined-using-rna-seq-analysis-in-patients-with-breast-cancer-following-cik-therapy
#6
Zuowei Hu, Xiaoye Zhang, Hang Yang, Shuanglai Qin, Yaqi Liu, Wei Xiong, Bing Yuan, Liping Li, Weiqi Yao, Dongcheng Wu
The present study aimed at investigating the underlying molecular mechanisms for patients following cytokine-induced killer (CIK) therapy, particularly involving the alterations in p53-associated signaling pathways, to elucidate whether CIK therapy serves a function in cancer treatment. Samples of blood were collected from patients with breast cancer prior to and following CIK therapy. Two group samples were used for RNA sequencing (RNA-Seq) to determine the alterations in gene expression levels following CIK therapy and one for the quantitative polymerase chain reaction (qPCR), to analyze the reliability of RNA-Seq results...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29247502/immunotherapy-excluding-checkpoint-inhibitors-for-stage-i-to-iii-non-small-cell-lung-cancer-treated-with-surgery-or-radiotherapy-with-curative-intent
#7
REVIEW
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo, Huan Song
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC...
December 16, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29184163/all-trans-retinoic-acid-enhances-cytotoxicity-of-cik-cells-against-human-lung-adenocarcinoma-by-upregulating-mica-and-il-2-secretion
#8
Xiao-Yan Fan, Peng-Yu Wang, Chao Zhang, Yu-Long Zhang, Yun Fu, Cong Zhang, Qiao-Xia Li, Jie-Na Zhou, Bao-En Shan, Dong-Wei He
To determine the growth inhibition capability of all-trans retinoic acid (ATRA) with cytokine-induced killer cells (CIKs), we evaluated their effects, alone and in combination, on human lung carcinoma A549 cells. CIKs treated with ATRA significantly inhibited cell growth. Additionally, CIK with ATRA synergistically inhibited migration and invasiveness, colony formation of A549 and NCI-H520 cells. Furthermore, analysis of apoptosis markers Bcl-2, Bax, Survivin and cleaved Caspase-3 showed that Bcl-2 and Survivin mRNA levels significantly decreased, and that Bax mRNA significantly increased, in the CIK + ATRA-treated cells, with corresponding effects on their respective proteins...
November 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29181186/enhanced-antitumor-effects-and-improved-immune-status-of-dendritic-cell-and-cytokine-induced-killer-cell-infusion-in-advanced-cancer-patients
#9
Feng Chen, Menghan Yang, Qingkun Song, Jiangping Wu, Xiaoli Wang, Xinna Zhou, Yanhua Yuan, Yuguang Song, Ni Jiang, Yanjie Zhao, Lei Zhou, Jun Ren
Little progress has been made in the treatment of advanced cancer. Dendritic cells (DCs) plus cytokine-induced killer (CIK) cells have exhibited antitumor effects. Thus, the aim of the present study was to evaluate the clinical efficacy of DC-CIK cell treatment in patients with advanced cancer. A paired study including 57 patients treated with DC-CIK cells (DC-CIK group) and 33 patients treated with best supportive care alone (BSC group) was performed. The patients in the DC-CIK group were matched to those in the control group in terms of sex, age, tumor type and clinical stage...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29180849/adjuvant-immunotherapy-of-dendritic-cells-and-cytokine-induced-killer-cells-is-safe-and-enhances-chemotherapy-efficacy-for-multiple-myeloma-in-china-a-meta-analysis-of-clinical-trials
#10
Yan Wang, Benji Lv, Ke Li, Anqi Zhang, Hong Liu
Objective: The aim of this study was to systematically evaluate the efficacy and safety of the combination of dendritic cells and cytokine-induced killer cells (DC-CIK) adjuvant immunotherapy and chemotherapy in the treatment of multiple myeloma (MM). Methods: Clinical trials were gathered by searching Web of Science, PubMed, Embase, Cochrane Library, Wanfang, and CNKI database. Outcome measurements including therapeutic efficacy, prognosis, immune function, and adverse events were extracted and evaluated...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29179719/effect-of-dendritic-cell-cytokine-induced-killer-cells-in-patients-with-advanced-colorectal-cancer-combined-with-first-line-treatment
#11
Yunqing Xie, Lijie Huang, Luchuan Chen, Xiaowei Lin, Li Chen, Qiuhong Zheng
BACKGROUND: Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients. These patients have a poor 5-year survival rate of 5% or less. Furthermore, a large dose of chemotherapy can produce adverse side effects and severe toxicity. Therefore, this retrospective study aimed to evaluate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell infusion as an adjuvant therapy in patients with advanced colorectal cancer combined with first-line treatment...
November 28, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29163711/identification-of-a-protein-associated-with-the-activity-of-cytokine-induced-killer-cells
#12
Jingsong Cao, Cong Chen, Yongqiang Gao, Li Hu, Yu Liang, Jianhua Xiao
Cytokine-induced killer cells (CIKs) adoptive immunotherapy for efficient antitumor ability is used clinically, but details regarding the proteins associated with CIK activity remain unclear. In the current study, the cytotoxicity of CIKs on hepatoma was identified to be significantly downregulated by 1.61-fold following gentamincin treatment. Further research revealed that a differentially expressed protein (P43) was significantly downregulated by 1.22-fold using one-dimensional gel electrophoresis analysis...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29158802/cytokine-induced-killer-cells-modulates-resistance-to-cisplatin-in-the-a549-ddp-cell-line
#13
Lili Yang, Chunjuan Du, Lei Wu, Jinpu Yu, Xiumei An, Wenwen Yu, Shui Cao, Hui Li, Xiubao Ren
Background Cytokine-induced killer (CIK) cells can potentially enhance the tumor-killing activity of chemotherapy. Objective This study aimed to evaluate the effects of CIK cells on cisplatin (DDP) resistance in the human lung adenocarcinoma cell line A549/DDP. Methods The detect resistance index, drug resistance related-genes and cytokine secretion of A549/DDP co-cultured with CIK cells were assayed in vitro. Results After A549/DDP co-culture with CIK cells, the DDP resistance of A549/DDP significantly decreased in a time-dependent manner...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29103317/anticancer-cellular-immunotherapies-derived-from-umbilical-cord-blood
#14
Katalin Balassa, Vanderson Rocha
Introduction The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies. Cellular immunotherapy involving the adoptive transfer of immune cells that potently recognize and eliminate malignantly transformed cells has become a promising new tool in the anticancer armory. Studies suggest that the unique biological properties of umbilical cord blood (UCB) cells could precipitate enhanced anticancer activity; hence, UCB could be an optimal source for immunotherapy with the potential to provide products with "off-the-shelf" availability...
November 6, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29073213/cytokine-induced-killer-cells-a-novel-treatment-for-allergic-airway-inflammation
#15
Panwadee Pluangnooch, Sunita Timalsena, Adisak Wongkajornsilp, Kitipong Soontrapa
The effectiveness of cytokine-induced killer (CIK) cells for treatment of cancers has long been appreciated. Here, we report for the first time that CIK cells can be applied to treat allergic airway inflammation. Adopting from an established protocol with some modifications, we generated CIK cells ex vivo from mouse T cells, and examined their effectiveness in treatment of allergic airway inflammation using the ovalbumin-induced model of allergic airway inflammation. Based upon evaluation of bronchoalveolar lavage cellularity, T helper type2 cytokine levels and lung histology, all of which are important parameters for determining the severity of allergic airway inflammation, diseased mice treated with CIK cells showed significant reductions in all the parameters without any obvious adverse effects...
2017: PloS One
https://www.readbyqxmd.com/read/29067881/autologous-cytokine-induced-killer-cell-immunotherapy-may-improve-overall-survival-in-advanced-malignant-melanoma-patients
#16
Yong Zhang, Yu'nan Zhu, Erjiang Zhao, Xiaolei He, Lingdi Zhao, Zibing Wang, Xiaomin Fu, Yalong Qi, Baozhen Ma, Yongping Song, Quanli Gao
AIMS: Our study was conducted to explore the efficacy of autologous cytokine-induced killer (CIK) cells in patients with advanced malignant melanoma. Materials & Methods: Here we reviewed 113 stage IV malignant melanoma patients among which 68 patients received CIK cell immunotherapy alone, while 45 patients accepted CIK cell therapy combined with chemotherapy. Results: We found that the median survival time in CIK cell group was longer than the combined therapy group (21 vs 15 months, p = 0...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29049237/effect-and-safety-of-cytokine-induced-killer-cik-cell-immunotherapy-in-patients-with-breast-cancer-a-meta-analysis
#17
Jianxin Hu, Junfeng Hu, Xiandong Liu, Chao Hu, Ming Li, Wei Han
BACKGROUND: Breast cancer (BC) is considered a systemic disease with a primarily locoregional component. The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed their safety and feasibility in treating BC. By searching the PubMed, Embase, CNKI, and Wanfang databases, we conducted a meta-analysis to assess the efficacy and safety of DC/CIK plus chemotherapy regimen (Exp) compared with chemotherapy (Con) alone regimen for breast carcinoma...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29029499/generation-and-characterization-of-erbb2-car-engineered-cytokine-induced-killer-cells-for-the-treatment-of-high-risk-soft-tissue-sarcoma-in-children
#18
Michael Merker, Verena Pfirrmann, Sarah Oelsner, Simone Fulda, Thomas Klingebiel, Winfried S Wels, Peter Bader, Eva Rettinger
Pediatric patients with recurrent, refractory or advanced soft tissue sarcoma (STS) who are simultaneously showing signs of cumulative treatment toxicity are in need of novel therapies. In this preclinical analysis, we identified ErbB2 as a targetable antigen on STS cells and used cytokine-induced killer (CIK) cells transduced with the lentiviral 2nd-generation chimeric antigen receptor (CAR) vector pS-5.28.z-IEW to target ErbB2-positive tumors. Solely CIK cell subsets with the CD3+ T cell phenotype showed up to 85% cell surface expression of the respective CAR...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29026316/clinical-effects-of-autologous-cytokine-induced-killer-cell-based-immunotherapy-in-the-treatment-of-endometrial-cancer-a-case-report-and-literature-review
#19
Yong Zhang, Yalong Qi, Axiang Wang, Baozhen Ma, Xiaomin Fu, Lingdi Zhao, Quanli Gao
Endometrial cancer is the most prevalent gynecological malignancy in the USA, and its treatment involves surgery, chemotherapy, and radiotherapy. Cytokine-induced killer (CIK) cell-based treatments have shown antitumor activity against several solid tumors. However, to the best of our knowledge, there are no reports yet of CIK immunotherapy in the treatment of endometrial cancer, and consequently, little is known about its efficacy and safety. Here, we report a case of an endometrial cancer patient receiving a combination treatment with CIK cells immunotherapy and chemotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28941416/increased-cycles-of-dc-cik-immunotherapy-decreases-frequency-of-tregs-in-patients-with-resected-nsclc
#20
Haiping Song, Shujuan Liu, Ziyun Zhao, Weihong Sun, Xiaofang Wei, Xuezhen Ma, Peng Zhao, Daiqing Gao
Regulatory T cells (Tregs) suppress antitumor immune responses. Cycles of Dendritic cells (DC) vaccination combined with cytokine-induced killer (CIK) cells (DC/CIK) treatment were significantly related with good prognosis. Therefore, we investigated whether increased cycles of immunotherapy could decrease frequency of Tregs in patients with resected non-small cell lung cancer (NSCLC). Previous study from our laboratory has determined that the optimal cutoff point of the cycle count was 3cycles. We examined the levels of Tregs and the related cytokines by flow cytometric and cytokine analysis in these patients after more than (≥) 3cycles or less than (<) 3cycles of DC/CIK cell treatment...
September 20, 2017: International Immunopharmacology
keyword
keyword
103213
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"